Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fixed combination of Azithromycin and Chloroquine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base. |
| Treatment B | ACTIVE_COMPARATOR | A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base. |
| Name | Type | Description |
|---|---|---|
| Fixed combination of Azithromycin and Chloroquine | DRUG | Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose. |
| Azithromycin and Chloroquine | DRUG | Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose. |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
The fixed combination of Azithromycin and Chloroquine is used for malaria. It is a small molecule drug being developed by Pfizer, Inc. (PFE) for the treatment of this infectious disease. The combination is currently in Phase 1 clinical development.
The fixed combination of Azithromycin and Chloroquine contains two active ingredients: azithromycin, a macrolide antibiotic, and chloroquine, an antimalarial agent. Chloroquine targets the malaria parasite, while azithromycin provides antibacterial activity. The combination is being studied for its potential in treating malaria.
The fixed combination of Azithromycin and Chloroquine is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for malaria.
The fixed combination of Azithromycin and Chloroquine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in active clinical trials.
The fixed combination of Azithromycin and Chloroquine has been studied in one completed Phase 1 clinical trial, identified as NCT00844207. This trial, conducted in the United States, enrolled 40 healthy volunteers and was designed to estimate the relative bioavailability of the fixed combination tablets compared to co-administered individual tablets of azithromycin and chloroquine.
The fixed combination of Azithromycin and Chloroquine is a tablet formulation that combines both drugs into a single dose, whereas azithromycin and chloroquine can also be given as separate tablets. A Phase 1 study (NCT00844207) was conducted to compare the relative bioavailability of the fixed combination tablets to co-administered individual tablets of azithromycin and chloroquine.